Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

11.44 +0.10 (+0.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Recap: Ocular Therapeutix Q4 Earnings
Ocular Therapeutix (NASDAQ:OCUL) reported its Q4 earnings results on Monday, February 28, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360
From Ocular Therapeutix, Inc.
Via Business Wire
Expert Ratings For Ocular Therapeutix
Ocular Therapeutix (NASDAQ:OCUL) has observed the following analyst rating... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix's Dexamethasone Ophthalmic Insert Meets Primary Goal In Dry Eye Disease Trial
Ocular Therapeutix Inc (NASDAQ: OCUL) announced topline results from its Phase 2 trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-... 
Via Benzinga
Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix Stock Gains As Court Invalidates Drug Delivery Patent From Mati
Ocular Therapeutix Inc (NASDAQ:OCUL) announce... 
Via Benzinga
Topics Intellectual Property
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Frequency Therapeutics (NASDAQ:FREQ) stock rose 10.94% to $7.51 during Tuesday's regular session. The current volume of 277.7K shares is 160.43% of Frequency... 
Via Benzinga
Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix: Q3 Earnings Insights
Ocular Therapeutix (NASDAQ:OCUL) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA®
From Ocular Therapeutix, Inc.
Via Business Wire
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •... 
Via Benzinga
Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ To Report Third Quarter 2021 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting
From Ocular Therapeutix
Via Business Wire
What 5 Analyst Ratings Have To Say About Ocular Therapeutix
Ocular Therapeutix (NASDAQ:OCUL) has observed the following analyst ratings... 
Via Benzinga
How The Future Looks For Last Week's Biggest Losers: Vinco Ventures, Atea Pharmaceuticals And More
Last week, the five biggest stock market losers declined between about 75% and 37%. Below is a look at each stock and what they may have in the cards going forward. Galera... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Wells Fargo boosted Bank of America Corporation (NYSE:B... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Progenity (NASDAQ:PROG) stock increased by 18.48% to $2.96 during Friday's regular session. Progenity's stock is trading at a volume of 116.0 million... 
Via Benzinga
Mid-Day Market Update: Snap Drops After Q3 Results; Creatd Shares Jump
Midway through trading Friday, the Dow traded up 0.25% to 35,690.68 while the NASDAQ fell 0.46% to 15,145.78. The S&P also rose, gaining 0.02% to 4,550.53. The U.S. has the... 
Via Benzinga
Topics Stocks
55 Biggest Movers From Friday
Gainers Phunware, Inc. (NASDAQ: PHUN) shares jumped 471.2% to close at $8.74 on Friday. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World... 
Via Benzinga
35 Stocks Moving In Friday's Mid-Day Session
Gainers Phunware, Inc. (NASDAQ: PHUN) rose 1099% to $18.35. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World Acquisition as traders circulated... 
Via Benzinga
Here's Why Ocular Therapeutix Stock Is Sinking Today
The company's experimental dry-eye treatment produced some disappointing clinical trial results. 
Via The Motley Fool
Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint
From Ocular Therapeutix, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.